CRNX · Crinetics Pharmaceuticals, Inc.
$84.78
+0.09 (+0.11%)
At close · Aug 24
Market Cap
$8.98B
Shares
106.07M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$84.78
Open$84.72
Day$84.71–84.81
52W close$30.09–84.78
Avg vol 30d3.0M
Short int5.9M · 5.5% float · 1.8d
Short vol21%
Last earningsAug 4, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 3
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 3, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
High
Market backdrop
VIX 15.9 · calm
Equity put/call 0.68
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+72%
above
Price vs 50-day avg
+21%
above
RSI (14)
90
overbought
MACD trend
Negative
52-week position
100%
near high
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+111%
trailing
YTD return
+82%
this year
Relative strength
+99%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $70 › 200d $49 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +62 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.53% of float · ▼ -5.6% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
266 holders — near 3-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
−74%
Y/Y
EPS growth
−34%
Y/Y
Free cash flow
$-383.7M
Balance sheet
$101.5M
net cash
Quant / Vol
risk profile
Volatility
113%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
0.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Non-GAAP operating expenses
· 2026
Non-GAAP
$480M – $520M
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
Cash used in operations
· For 2025
$340M – $370M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+72%
Bullish
Price vs 50-day avg
+21%
Bullish
RSI (14)
90
Bearish
MACD trend
Negative
Bearish
52-week position
100%
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $70 › 200d $49 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +62 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.53% of float · ▼ -5.6% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
266 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $30
Now $85 · 100%
Range high $85
vs 200-day avg +72%
vs 50-day avg +21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| enrollment forms received | 245 | the second quarter of 2026 | — |
|
|
|||
| Net Product Revenue | $24M | Q2 2026 | — |
| percentage of patients treated with PALSONIFY on reimbursed therapy | 70% | at the end of the second quarter of 2026 | — |
|
|
|||
| Net product revenue from the U.S. commercial launch of PALSONIFY | $5.4M | fourth quarter ended December 31, 2025 | — |
| Non-GAAP operating expenses non-GAAP | $428.48M | year ended December 31, 2025 | — |
GAAP → non-GAAP reconciliationGAAP GAAP operating expenses 524.47M
-1.08M Cost of product revenue
-91.02M Stock-based compensation
-3.89M Depreciation and amortization
= Non-GAAP operating expenses 428.48M
|
|||
| Cash, cash equivalents, and investments | $1.4B | as of January 8, 2026 | — |
| Net product revenue from PALSONIFY | $5M | fourth quarter of 2025 | — |
| Unique PALSONIFY prescribers | 125 | fourth quarter of 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRNX
this stock
Crinetics Pharmaceuticals, Inc.
|
$8.98B | +82.1% | -74.1% | — | 5.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.8% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.30B | +7.3% | +20.8% | 20.5 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +20.2% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRNX | +0.0% | +1.1% | +111.3% | +1.5% | +82.1% |
| SPY | -1.2% | +3.3% | +12.2% | +2.2% | +12.0% |
| vs SPY | +1.2% | -2.2% | +99.1% | -0.7% | +70.2% |
Key facts
CIK
1658247
CUSIP
22663K107
13F (30d)
256 filings
235 filers
Visit website
Investor relations